A method, and system, to induce remission in diseases characterized by excessproduction of sTNR and interleukin 2 has been developed. In the most preferredembodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2Rimmobilized in a column containing a material such as SEPHAROSETM. The patientis connected to a pheresis machine which separates the blood into the plasmaand red cells, and the plasma is circulated through the column until thedesired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferablyto less than normal levels. In the preferred method, patients are treatedthree times a week for four weeks. This process can be repeated after a periodof time. Clinical studies showed reduction in tumor burden in patients havingfailed conventional chemotherapy and radiation treatments.
